SCHEMBL6501611

SCHEMBL6501611

O=CC(c1ccncc1)c1cc(Cl)cc(Cl)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 3/20 0.42
MAPK1 P28482 2/20 0.38
ROCK2 O75116 1/20 0.38
RPS6KA5 O75582 1/20 0.38
MAP4K4 O95819 1/20 0.38
PRKACA P17612 1/20 0.38
RPS6KB1 P23443 1/20 0.38
AKT1 P31749 1/20 0.38
AKT2 P31751 1/20 0.38
GSK3A P49840 1/20 0.38
GSK3B P49841 1/20 0.38
PRKX P51817 1/20 0.38
NEK4 P51957 1/20 0.38
PRKCD Q05655 1/20 0.38
PRKG2 Q13237 1/20 0.38
ROCK1 Q13464 1/20 0.38
PRKG1 Q13976 1/20 0.38
PKN2 Q16513 1/20 0.38
CDC42BPA Q5VT25 1/20 0.38
HIPK4 Q8NE63 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5184111 0.85 CYP19A1 (0.61) CYP19A1MAPK1AKT1FFAR2CYP11B1
SCHEMBL3907301 0.84 CYP19A1 (0.41) CYP19A1MAPK1ROCK2GSK3BROCK1
SCHEMBL1515718 0.81 IDO1 (0.46) CYP2D6KMT2AALDH1A1MEN1
SCHEMBL6499767 0.78 CYP3A4 (0.35) CYP19A1CYP3A4SLC6A2SLC6A4SLC6A3
SCHEMBL1515763 0.76 SLC6A3 (0.58) CYP2D6SLC6A2SLC6A4SLC6A3KMT2A
SCHEMBL3658338 0.76 MEN1 (0.46) CYP19A1CYP3A4CYP2D6SLC6A4CYP2C19
SCHEMBL2789136 0.73 LTA4H (0.42) CYP19A1CYP11B1CYP11B2KMT2AMEN1
SCHEMBL6504970 0.73 CYP19A1 (0.39) CYP19A1CYP3A4SLC6A2SLC6A4SLC6A3
SCHEMBL8309987 0.73 LMNA (0.42) CYP19A1CYP3A4SLC6A2SLC6A4SLC6A3
SCHEMBL14834576 0.71 CYP19A1 (0.42) CYP19A1MAPK1MAP4K4FFAR2SLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050080113-A1 Medicinal compositions TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-04-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050080113-A1 Medicinal compositions TNF, TRAF6, MMP8 CYP19A1 2827/4885MAPK1 4/4885ROCK2 102/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.